Corcept Therapeutics Incorporated (CORT) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Total Cash From Operating Activities Chart for Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated (CORT) operating cash flow for FY2025 was USD 142.0M, a -28.3% change from FY2024. Corcept Therapeutics Incorporated's operating cash flow moved from USD -10.0M in 2003 to USD 142.0M in 2025 over 22 years. Operating cash flow compound annual growth rate: 5-year CAGR of -1.3%, 10-year CAGR of 46.4%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$12.93B
Implied Share Price
$119.57
Enterprise Value
$11.89B
Revenue (TTM)
$830.81M
EBITDA
$8.08M
Profit Margin
6.64%
Trailing P/E
271.75
Forward P/E
19.30
Price/Book (MRQ)
18.00
Price/Sales (TTM)
15.56
EV/EBITDA
1405.48
EV/Revenue
14.93
Dividend Yield
—
Book Value
$6.54
Free Cash Flow (FY2025)
$141.78M
Free Cash Flow Yield
1.10%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.